Homocysteine and B vitamins in cognitive impairment

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN94410159

Enrollment

300

Registered

2005-06-21

Start date

2004-04-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Impairment Mental and Behavioural Disorders Cognitive Impairment

Interventions

Two groups: placebo and treated with folic acid (0.8mg), vitamin B12 (0.5mg) and vitamin B6 (20mg) for two years. Follow-up: telephone memory test at 30 months after start.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects with mild cognitive impairment 70 years and older

Exclusion criteria

Exclusion criteria: 1. Dementia 2. Treatment with drugs for dementia 3. Active cancer 4. Vitamin B12 injections 5. Stroke within last three months 6. Inability to undergo Magnetic Resonance Imaging (MRI) scan

Design outcomes

Primary

Measure	Time frame
1. Rate of shrinkage of whole brain and or brain regions assessed by volumetric MRI 2. Changes in performance on a variety of cognitive tests	—

Secondary

Measure	Time frame
1. Trial recruitment procedures 2. Conversion to dementia	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 30, 2026